Immuno-Biological Laboratories Co., Ltd. (TYO:4570)

Japan · Delayed Price · Currency is JPY

1,068.00

+17.00 (1.62%)

Aug 27, 2026, 12:44 PM JST

TYO:4570 Financials Overview

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Revenue & Profits

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	1,079	1,004	969	816	794	647
Revenue Growth	13.46%	3.61%	18.75%	2.77%	22.72%	7.47%
Gross Profit	777	706	634	516	526	376
Operating Income	345	281	209	110	52	-122
Net Income	369	329	249	186	-289	-258
Earnings Per Share	39.62	35.33	26.74	19.97	-31.03	-27.70
EPS Growth	43.02%	32.13%	33.87%	-	-	-

Revenue by Segment

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Antibody Related Business	1,002	964.37	812.85	790.6	637.47
Cosmetics Related	2.68	5.16	3.85	4.02	13.35
Total	1,005	969.53	816.7	794.62	647.58

Cash & Debt

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Investments	907	989	825	734	614	508
Total Debt	171	176	204	235	234	233
Net Cash (Debt)	736	813	621	499	380	275
Net Cash Growth	4.10%	30.92%	24.45%	31.32%	38.18%	-46.50%
Net Cash Per Share	79.03	87.29	66.68	53.58	40.80	29.53

Cash Flow & CapEx

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Operating Cash Flow	-	301	183	133	26	-93
Capital Expenditures	-	-33	-59	-16	-	-
Free Cash Flow	-	268	124	117	26	-93
Free Cash Flow Growth	-	116.13%	5.98%	350.00%	-	-

Margins

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Gross Margin	72.01%	70.32%	65.43%	63.23%	66.25%	58.11%
Operating Margin	31.97%	27.99%	21.57%	13.48%	6.55%	-18.86%
Pretax Margin	32.62%	29.98%	21.67%	15.20%	-35.26%	-38.64%
Profit Margin	34.20%	32.77%	25.70%	22.79%	-36.40%	-39.88%
FCF Margin	-	26.69%	12.80%	14.34%	3.28%	-14.37%

Dividends

Fiscal Year	Current	FY 2026
Period Ending	Aug '26 Aug 27, 2026	Mar '26 Mar 31, 2026
Dividend Per Share	7.500	6.000
Dividend Per Share Growth	0%	-
Dividend Yield	0.73%	0.45%

Valuation

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug '26 Aug 27, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
PE Ratio	26.53	37.99	17.95	26.49	-	-
P/FCF Ratio	36.52	46.64	36.05	42.11	145.79	-
PS Ratio	9.07	12.45	4.61	6.04	4.77	4.71